Investment analysts at StockNews.com assumed coverage on shares of Chembio Diagnostics (NASDAQ:CEMI – Get Rating) in a report issued on Wednesday. The brokerage set a “hold” rating on the stock.
Chembio Diagnostics Stock Performance
CEMI opened at $0.46 on Wednesday. Chembio Diagnostics has a fifty-two week low of $0.19 and a fifty-two week high of $1.24. The company has a fifty day moving average of $0.43 and a two-hundred day moving average of $0.37. The stock has a market capitalization of $16.71 million, a price-to-earnings ratio of -0.38 and a beta of 1.85.
Insider Buying and Selling at Chembio Diagnostics
In other news, major shareholder Credit Advisors Ll Perceptive acquired 339,000 shares of the business’s stock in a transaction on Thursday, April 6th. The stock was bought at an average price of $0.44 per share, with a total value of $149,160.00. Following the completion of the acquisition, the insider now owns 4,425,100 shares of the company’s stock, valued at $1,947,044. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders bought 1,055,578 shares of company stock valued at $468,371. Corporate insiders own 3.30% of the company’s stock.
Institutional Investors Weigh In On Chembio Diagnostics
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
- Get a free copy of the StockNews.com research report on Chembio Diagnostics (CEMI)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.